Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells

@article{Park2008BlockageOI,
  title={Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells},
  author={Juwon Park and Kwang Sung Ahn and Eunkyung Bae and Byung Su Kim and Byoung Kook Kim and Young Y. Lee and Sung-Soo Yoon},
  journal={Anti-Cancer Drugs},
  year={2008},
  volume={19},
  pages={777-782}
}
The transcription factor nuclear factor-kappa B (NF-κB) regulates the transcription of a number of genes involved in a variety of cellular responses, including cell survival, inflammation, and differentiation. NF-κB is activated by a variety of stimuli, proinflammatory cytokines, mitogens, growth factors, and stress-inducing agents. Aberrant NF-κB expression is considered to be one of the oncogenic factors of cancer and the constitutive activation of NF-κB is observed in several hematologic… 
Phosphorylation of signal transducer and activator of transcription 1 reduces bortezomib-mediated apoptosis in cancer cells
TLDR
The results provide the first evidence that STAT1 phosphorylation can play a role in bortezomib resistance by exerting antiapoptotic effects and suggest the possibility to abolish or reduce bortzomib chemoresistance in ovarian cancer by the addition of cisplatin or JAK inhibitors.
Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis
TLDR
The findings provide the basis for developing therapeutic strategies in bortezomib-resistant relapsed and refractory MM patients and identify genes related to ubiquitination that were differentially regulated in U266/velR.
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
TLDR
This review summarizes published research on the role of IL-6 in myeloma development and describes ongoing efforts by the University of Iowa Myeloma Multidisciplinary Oncology Group to develop new approaches to the design and testing ofIL-6-targeted therapies and preventions of MM.
IL-6 and MYC collaborate in plasma cell tumor formation in mice.
TLDR
The newly developed mouse strains may provide a good preclinical research tool for the design and testing of new approaches to target IL-6 in treatment and prevention of human PCNs.
Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti–IL-6 Antibody
TLDR
The fact that IL-6 is not the preponderant actor of cell resistance to cytotoxics and ionizing radiations, which seems to be regulated by a complex network of proteins, supports the idea that monoclonal antibodies directed againstIL-6 may enable to reverse resistance of cancer cell lines.
Molecular Mechanisms of Bortezomib Action: Novel Evidence for the miRNA–mRNA Interaction Involvement
TLDR
Examination of changes in global gene and miRNA expression and analyzed the identified miRNA–mRNA interactions after bortezomib exposure in human neuroblastoma cells to define pathways affected by this agent in this type of cells found that 719 genes and 28 miRNAs were downregulated, and 319 genes and 61 mi RNAs were upregulated in neuroblast cancer cells treated with bortzomib.
Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine
TLDR
An overview of DLBCL is presented and techniques such as gene expression studies, including next-generation sequencing, which have enabled a more understanding of the complex pathogenesis ofDLBCL and have helped determine molecular targets for novel therapeutic agents are discussed.
Targeted Inhibition of Multiple Proinflammatory Signalling Pathways for the Prevention and Treatment of Multiple Myeloma
TLDR
This poster presents a probabilistic procedure to construct a ‘spatially distinct response’ to the excisional excision of central nervous system disease.
Quinazoline-sulfonamides as potential antitumor agents: synthesis and biological testing
TLDR
A new series of quinazoline containing sulfonamide derivatives showed remarkable antitumor activity almost similar to that of the standard drug (doxorubicin), while few compounds were totally inactive.
The tumor microenvironment is critical for the development of plasma cell neoplasia in mice
TLDR
The author thanks his mentor, Siegfried Janz, and former members of the Janz laboratory, who was willing to help him with western blots on one day, and the next debate some of the unanswerable questions in life.
...
1
2
...

References

SHOWING 1-10 OF 30 REFERENCES
Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications
TLDR
It is demonstrated that IGF-1 stimulates sustained activation of NF-κB and Akt; induces phosphorylation of the FKHRL-1 Forkhead transcription factor; upregulates a series of intracellular anti-apoptotic proteins including FLIP, survivin, cIAP-2, A1/Bfl-1, and XIAP; and decreases Apo2L/TRAIL-sensitivity of MM cells.
Activation in vitro of NF-κB" by phosphorylation of its inhibitor IκB"
TLDR
An in vitro system in which addition of purified protein kinases to a partially purified NF-κB/IκB complex leads to the activation of the DNA-binding activity of NF-σB is used, which acts as a second messenger system, transducing activation signals from the cytoplasm to the nucleus.
NF-κB as a Therapeutic Target in Multiple Myeloma*
TLDR
These studies demonstrate that specific targeting of NF-κB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
TLDR
It is suggested that a strategy combining UCN-01 with disruption of the IkappaB kinase (IKK)/IkappaB/NF-kappa B pathway warrants attention in MM.
NF-kappa B as a therapeutic target in multiple myeloma.
TLDR
It is demonstrated that specific targeting of NF-kappaB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu.
NF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, But is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cells
TLDR
A systematic analysis of the functional roles of the four major transcriptional regulatory sites present in the IL-6 promoter region indicates a novel transcriptional mechanism for NF-kappaB in the activation of NF- kappaB-driven genes.
The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications
TLDR
Agents which act to inhibit TNFα may abrogate the paracrine growth and survival advantage conferred by MM cell adhesion in the BM microenvironment.
Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines
TLDR
It is demonstrated for the first time that inhibiting JNK activity induces growth arrest and activates NF-κB in MM cells.
Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2.
TLDR
The data suggest that the protective effects of bcl-2 in MM cells act upstream in the NF-kappaB activation-signaling pathway and the potential use of NF- kappaB as a biomarker in progressive MM.
...
1
2
3
...